Literature DB >> 21920190

Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel.

Anna Glasier1, Sharon T Cameron, Diana Blithe, Bruno Scherrer, Henri Mathe, Delphine Levy, Erin Gainer, Andre Ulmann.   

Abstract

BACKGROUND: Emergency contraception (EC) does not always work. Clinicians should be aware of potential risk factors for EC failure. STUDY
DESIGN: Data from a meta-analysis of two randomized controlled trials comparing the efficacy of ulipristal acetate (UPA) with levonorgestrel were analyzed to identify factors associated with EC failure.
RESULTS: The risk of pregnancy was more than threefold greater for obese women compared with women with normal body mass index (odds ratio (OR), 3.60; 95% confidence interval (CI), 1.96-6.53; p<.0001), whichever EC was taken. However, for obese women, the risk was greater for those taking levonorgestrel (OR, 4.41; 95% CI, 2.05-9.44, p=.0002) than for UPA users (OR, 2.62; 95% CI, 0.89-7.00; ns). For both ECs, pregnancy risk was related to the cycle day of intercourse. Women who had intercourse the day before estimated day of ovulation had a fourfold increased risk of pregnancy (OR, 4.42; 95% CI, 2.33-8.20; p<.0001) compared with women having sex outside the fertile window. For both methods, women who had unprotected intercourse after using EC were more likely to get pregnant than those who did not (OR, 4.64; 95% CI, 2.22-8.96; p=.0002).
CONCLUSIONS: Women who have intercourse around ovulation should ideally be offered a copper intrauterine device. Women with body mass index >25 kg/m(2) should be offered an intrauterine device or UPA. All women should be advised to start effective contraception immediately after EC.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21920190     DOI: 10.1016/j.contraception.2011.02.009

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  49 in total

1.  Results from pooled Phase III studies of ulipristal acetate for emergency contraception.

Authors:  Caroline Moreau; James Trussell
Journal:  Contraception       Date:  2012-07-06       Impact factor: 3.375

Review 2.  Obesity and contraception.

Authors:  Sheila K Mody; Michelle Han
Journal:  Clin Obstet Gynecol       Date:  2014-09       Impact factor: 2.190

3.  Copper intrauterine device placement 6-14 days after unprotected sex.

Authors:  Ivana Thompson; Jessica N Sanders; E Bimla Schwarz; Christy Boraas; David K Turok
Journal:  Contraception       Date:  2019-06-07       Impact factor: 3.375

Review 4.  Emergency contraception. Widely available and effective but disappointing as a public health intervention: a review.

Authors: 
Journal:  Hum Reprod       Date:  2015-02-11       Impact factor: 6.918

Review 5.  Mechanism of action of levonorgestrel emergency contraception.

Authors:  Chris Kahlenborn; Rebecca Peck; Walter B Severs
Journal:  Linacre Q       Date:  2015-02

Review 6.  Emergency contraception review: evidence-based recommendations for clinicians.

Authors:  Kelly Cleland; Elizabeth G Raymond; Elizabeth Westley; James Trussell
Journal:  Clin Obstet Gynecol       Date:  2014-12       Impact factor: 2.190

Review 7.  Sexual Assault in Adolescents.

Authors:  Christine Banvard-Fox; Meredith Linger; Debra J Paulson; Lesley Cottrell; Danielle M Davidov
Journal:  Prim Care       Date:  2020-02-27       Impact factor: 2.907

8.  UPA > LNG, but Not Good Enough.

Authors:  Kristina Gemzell-Danielsson; James Trussell
Journal:  Contraception       Date:  2013-08-21       Impact factor: 3.375

9.  "My BMI is too high for Plan B." A changing population of women seeking ulipristal acetate emergency contraception online.

Authors:  Kelly Cleland; Brandon Wagner; Nicole K Smith; James Trussell
Journal:  Women Health       Date:  2019-07-08

10.  Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users.

Authors:  Alison B Edelman; Ganesh Cherala; Myrna Y Munar; Barent Dubois; Martha McInnis; Frank Z Stanczyk; Jeffrey T Jensen
Journal:  Contraception       Date:  2012-11-12       Impact factor: 3.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.